Context:The concept of quality of life (QoL) is becoming an important measure of the impact of psychiatric disorders. It is natural that once patient achieves remission, QoL would improve, but very few studies are conducted under this phase. This study compares the differences in QoL in remitted patients with monotherapy and polypharmacy.Aims:The aim of this study is to compare the QoL between psychiatric patients in remission treated with monotherapy and polypharmacy.Settings and Design:It is a questionnaire based cross-sectional comparative study.Materials and Methods:This study included outpatients under remission who come for follow-up in psychiatric department. Semi-structured data collection form was used. Remission was confirmed using suitable scales, and QoL was assessed using the World Health Organization quality of life-Brief (WHOQOL-BREF) scale. Clinical Global Impression (CGI) and Global Assessment of Functioning (GAF) were applied to understand the overall improvement and functioning levels.Results:Out of the total 100 patients enrolled in the study, fifty patients were on monotherapy and fifty patients on polypharmacy. The cost of medication was comparatively high for polypharmacy (Rs. 3568.92 [±348.54]) than monotherapy (Rs. 1936.56 [±252.07]). The QoL in physical, psychological, and social domains was significantly high in patients on polypharmacy rather than monotherapy when assessed using the WHOQOL-BREF scale. Ninety-six percent of monotherapy patients had CGI scores between 1.5 and 2.4 while 74% of polypharmacy patients had scores between 1.0 and 1.5. Ninety-six percent of monotherapy patients had <80 GAF scores while 92% of polypharmacy patients had >80.Conclusions:Patients treated with polypharmacy had better QoL and also clinical improvement and functioning levels were superior.

Dapagliflozin which is also known as Farxiga in the US and Forxiga in the EU is a drug which was developed by Bristol-Myers Squibb in partnership with Astra Zeneca. It is also available in Oxra and it is marking by Sun Pharmaceutical Industries Ltd. It contains the active substance Dapagliflozin which is the second member of selective sodium glucose co-transporter-2 (SGLT-2) inhibitor and it is the first group among oral anti-diabetic agents which are independent of insulin secretion. The drug Dapagliflozin shows the action of reducing the blood glucose by preventing the reabsorption of glucose at the renal proximal tubule and avoids insulin resistance. It is a new molecule that helps in maintaining the glycemic control either in mono therapy or combinational therapy or add on therapy. This is a review article which summarizes the details of Dapagliflozin.

Hair loss (alopecia) is an occasional side effect associated with psychotropic drugs use. Fluvoxamine is a synthetic antidepressant which acts as a selective serotonin reuptake inhibitor as well as sigma-1 receptor agonist. Psychotropic drugs are considered to cause hair loss by affecting the telogenic phase of hair follicle. Here we present a case of a 28 year old male patient reported with diffuse hair loss after administration of fluvoxamine and condition remitted after cessation of the drug. Our report suggests the possibility of developing alopecia with fluvoxamine use.